

Stock Code: 300760

Stock Abbreviation: Mindray

No.: 2024-005

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.**Record of Investor Relations Activities**Time Period: 13th May – 29th July

Introduction to the Main Content of Investor Relations Activities	<p>1. Interactive Q&A</p> <p>Q: Could you please update the progress of the medical equipment renewal project in China? How do you foresee the trend in domestic medical equipment procurement in the second half of the year compared to the first half?</p> <p>A: In March of this year, the State Council issued a notice regarding the "Action Plan for Promoting Large-scale Equipment Renewal and the Replacement of Consumer Goods", which explicitly addressed the advancement of equipment and IT infrastructure upgrades in healthcare institutions. It encourages eligible healthcare institutions to expedite the renewal and upgrades of medical equipment, enhance hospital wards, and rectify deficiencies in ward environments and facilities. Following this, the company has closely monitored the project's progress, with various departments such as marketing, R&D, and production supply chain all prepared for related work. Recently, the National Development and Reform Commission and the Ministry of Finance issued a notice on several measures to support large-scale equipment renewal and the replacement of consumer goods, specifically mentioning the allocation of approximately CNY 300 billion in ultra-long-term special government bonds to bolster these efforts. Additionally, local development and reform commissions, finance departments, and health commissions have successively announced their plans for medical equipment renewal over the past few months. Although the domestic procurement process inevitably experienced delays in the second quarter due to the equipment renewal project, the rigid demand for medical equipment procurement persists. It is expected that the procurement situation in the second half of the year will improve compared to the first half. If the planned issuance of ultra-long-term special government bonds and the</p>
--	---

medical equipment renewal project are implemented as scheduled within this year, we remain confident in achieving the annual growth targets. Thanks to the unique competitive advantage brought by our integrated smart solutions encompassing equipment, IT, and AI, we are confident in delivering market performance significantly faster than the industry average and surpassing our main competitors under any circumstances.

Q: As a crucial high-growth segment for the company, the progress of the CLIA business has always been a focal point for the capital market. How is the business currently developing?

A: The CLIA business, a key driver of the company's growth over the past few years and for the foreseeable future, has always been a high priority for Mindray. We have consistently made substantial investments in R&D, marketing, and supply chain for this business segment.

Among them, a significant investment was the acquisition of HyTest. In the nearly three years since the acquisition, the integration of HyTest has progressed smoothly, and last year, we launched the industry-leading high-sensitivity cardiac troponin hs-cTnI. This year, the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) updated the reference table for cardiac troponin reagent performance among major global IVD manufacturers, ranking Mindray's hs-cTnI reagent first among all. The superior performance of our reagents led to a revenue growth rate of over 60% for the cardiac marker tests last year, far exceeding the average growth rate of the CLIA business.

As reagent performance continues to improve, the technological level of our IVD instruments has gradually reached an industry-leading position, highlighted by the launch of the MT 8000 Laboratory Automation System (Phase II) this year.

The installation of TLA will also increase, driving our IVD business into more domestic top-tier hospitals and overseas medium to large volume labs.

According to company statistics, our domestic market share in the CLIA business is expected to surpass another imported brand this year.

Moreover, the development of the next-generation high-end CLIA

instruments is progressing smoothly.

Despite the remarkable progress in the CLIA business over the past few years, Mindray still has a long way to go. In the domestic accessible market worth CNY 40 billion, Mindray's market share remains in single digits, and its overseas share is even negligible. Therefore, the CLIA business will continue to be one of the key drivers of our growth in the long term.

Q: What is the current product layout of the minimally invasive surgery business? Has the time come for this business to start gaining momentum?

A: With the launch of the 4K+fluorescence and 4K+3D thoraco-abdominal rigid endoscopic systems, along with supporting instruments and consumables such as electrosurgical scalpels, ultrasonic surgical & electrosurgical energy platform, and endoscopic staplers needed for thoraco-abdominal surgeries, the company has essentially completed its product layout for minimally invasive surgery. The product competitiveness has reached a leading level domestically.

Take the intelligent endoscopic stapler launched this year as an example. Wound closure is a high-risk procedure during surgery, making product safety crucial. With built-in chips and intelligent algorithms, our stapler actively adjusts firing speed based on different tissue characteristics, effectively mitigating the risk of extreme situations. This results in a staple formation success rate exceeding 98%, on par with imported brands. Next, the company will actively participate in domestic volume-based procurement of products such as ultrasonic scalpels and endoscopic staplers, aiming for rapid market expansion.

Although thoraco-abdominal surgeries constitute a significant portion, minimally invasive surgery covers a wide range. In the future, while iteratively upgrading thoraco-abdominal surgical products, the company will enter new minimally invasive surgery fields and strategically explore the surgical robotics business, cultivating new growth drivers for the company's long-term rapid development.

Q: If the US government further increases tariffs on Chinese exports to the US, what measures will the company take in response?

A: Mindray's products are available in over 190 countries and regions, with overseas revenue accounting for 38.79% of the company's total revenue in 2023, of which the North American market constitutes 7.45%. Since the onset of the US-China trade friction in 2018, the company has been closely monitoring negotiations and proactively adjusting our strategies. Even with the imposition of a 25% tariff, Mindray's progress in the US market has not stalled. Currently, the company covers more than 80% of the Integrated Delivery Network (IDN) in the US. By continuously expanding the high-end customers and increasing their revenue contribution, the profitability of Mindray's US business has steadily improved over the past few years, making the US one of Mindray's most profitable markets globally.

To address the associated policy risks, we are implementing the following measures: first, accelerating the establishment of overseas localization production facilities, with more than 10 such bases, including in Mexico, expected to be operational by the end of this year; second, further enhancing the overall competitiveness of products to mitigate the impact of tariffs on profit margins; third, intensifying efforts to expand into high-end markets, thereby effectively increasing product market share and strengthening overall profitability.

Other: This event does not involve any undisclosed significant information. Other communication content has been disclosed in previously released investor relations activity records.